Summit Therapeutics is holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicinal therapies. Co.'s primary product candidate, ridinilazole, is an oral small molecule antibiotic in clinical trial program, which evaluating ridinilazole for treating patients suffering from clostridioides difficile infection. Co.'s other product candidate, SMT026738 (SMT-738), is a small molecule inhibitor of bacterial lipoprotein transport system treating multidrug resistant infections, including Carbapenem-resistant Enterobacteriaceae infections. SMT-738 is an antibiotic that has entered preclinical development. The SMMT stock yearly return is shown above.
The yearly return on the SMMT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SMMT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|